Bigelow Investment Advisors LLC Reduces Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Bigelow Investment Advisors LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,213 shares of the medical research company’s stock after selling 30 shares during the period. Bigelow Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,175,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. Savant Capital LLC boosted its stake in Thermo Fisher Scientific by 0.5% during the fourth quarter. Savant Capital LLC now owns 3,627 shares of the medical research company’s stock worth $1,997,000 after buying an additional 18 shares during the period. 1776 Wealth LLC increased its holdings in Thermo Fisher Scientific by 2.4% in the 4th quarter. 1776 Wealth LLC now owns 799 shares of the medical research company’s stock valued at $440,000 after purchasing an additional 19 shares during the last quarter. Sugarloaf Wealth Management LLC lifted its stake in Thermo Fisher Scientific by 6.9% during the fourth quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock worth $156,000 after purchasing an additional 19 shares in the last quarter. Rosenberg Matthew Hamilton grew its stake in shares of Thermo Fisher Scientific by 3.7% in the fourth quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock valued at $279,000 after buying an additional 19 shares in the last quarter. Finally, Tsfg LLC raised its holdings in shares of Thermo Fisher Scientific by 8.3% in the 4th quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock valued at $132,000 after buying an additional 19 shares during the period. Institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the transaction, the chief executive officer now directly owns 49,155 shares in the company, valued at approximately $27,311,992.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock worth $28,513,384 over the last 90 days. 0.32% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on TMO. Barclays lowered shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $475.00 to $555.00 in a research note on Wednesday, January 24th. Raymond James raised their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. HSBC boosted their target price on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Citigroup assumed coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective for the company. Five analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $604.69.

Thermo Fisher Scientific Stock Performance

TMO traded up $3.26 during trading on Friday, hitting $544.78. 1,738,308 shares of the stock were exchanged, compared to its average volume of 1,549,863. The firm has a market capitalization of $207.95 billion, a P/E ratio of 35.21, a PEG ratio of 2.30 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The stock has a fifty day moving average price of $571.39 and a two-hundred day moving average price of $527.11. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. During the same period last year, the firm posted $5.40 EPS. Thermo Fisher Scientific’s revenue for the quarter was down 4.9% on a year-over-year basis. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a $0.39 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.